Unfold More of Your Story
Most people with HR+/HER2- advanced breast cancer can maintain a good quality of life throughout their first line of treatment. But when their cancer progresses, the devastation hits hard. They are now consumed with worry that their next treatment will change everything dramatically, from how they feel and live to how they plan their lives and spend time with their loved ones. TRUQAP can help these people unfold more of their beautiful, unique lives. This second-line treatment delivers both impressive efficacy and tolerability, allowing people to continue living their daily lives without fear of major lifestyle changes. TRUQAP provides people with a beautiful promise to both help them keep their cancer at bay on their terms and have hope for unfolding more of their story, because neither advanced breast cancer nor their cancer treatment should stop them from living one adventurous tomorrow after another. DTC campaign launched 11/23. TV spot aired 3/25.
Red Flag
Prostate cancer is the most common cancer type among biological males with 1 in 8 having it in their lifetime. And as a hormone-driven cancer, precision medicine treatments have lagged behind other cancer types. With a new targeted therapy on the horizon, 1 in 4 men with mHSPC can finally receive a treatment designed for their exact type of prostate cancer. But only if doctors see their giant Red Flag.
The Bold TRUth
With “TRU” in the brand name, the campaign focuses on a bold promise of TRUth that is only possible when TRUQAP is chosen. The TRUQAP/FALSE quiz device overlaid on watercolor renderings of a diverse group of women highlights the gravity of what’s at stake when making 2L treatment choices while celebrating the unique human beings affected by the outcomes of this choice. This US/Global HCP launch campaign leverages the powerful efficacy TRUQAP offers, but post-launch iterations will be a veritable library of TRUe reasons to believe in TRUQAP.
PRIME SUSPECT
The search for relevant biomarkers in the ever-evolving oncology landscape is nothing short of an all-out manhunt. Lately, there’s been chatter that the mystery of whether the AKT protein is a viable target is close to being solved. Researchers have been gathering string on the central protein of the PI3K/AKT/PTEN pathway for years, and it turns out AKT has had the motive, means, and location to drive disease progression this whole time. InvestigateAKT.com launched at ASCO ‘23.
Unlock a Brighter Future
US/Global HCP Unbranded campaign for HR+/HER2- metastatic breast cancer. UnlockmBC.com launched at SABCS ‘21.
More to the Story
US HCP unbranded campaign for HER2+ metastatic breast cancer. NEJM print ad & MoretomAbs.com. Launched at ASCO ‘19.
